Poirier Valerie J, Meier Valeria, Turek Michelle, Christensen Neil, Bowal Jacqueline, Ponzini Matthew D, Keller Stefan M
Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Clinic for Radiation Oncology & Medical Oncology, Vetsuisse Faculty Zurich, University of Zurich, Zurich, Switzerland.
Vet Comp Oncol. 2025 Mar;23(1):82-89. doi: 10.1111/vco.13032. Epub 2024 Dec 4.
The standard of care treatment for localised feline nasal lymphoma (FeNL) is radiation therapy (RT). Early local or systemic failure occurs in 17%-45% of cats treated with RT with or without chemotherapy. The aim of this study was to determine if pre-treatment biopsy characteristics could predict early tumour progression in FeNL. Inclusion criteria consisted of histologically confirmed FeNL, available paraffin blocks of diagnostic quality, localised to the sinonasal cavity on staging pre-RT, treated with IMRT/IGRT (10 × 4.2 Gy) without chemotherapy and at least 1 year follow-up. All pre-RT biopsies were reviewed and evaluated with CD3, CD20, CD79a, pan-CK and Ki-67 immunohistochemistry and the mitotic activity index was determined. The primary endpoint was progression-free survival (PFS) at 1 year and hazard-ratios (HR) with confidence interval (CI) were calculated. Twenty-eight cats fit the inclusion criteria, and all had diffuse large B-cell lymphoma. Seventeen cats (61%) were progression free at 1 year. Of the 11 cats that progressed in the first year, two had local progression, two had both local and systemic progression and seven had systemic progression. The mitotic index (HR: 1.03, CI 0.9-1.19, p = 0.645), Ki-67 (HR: 1.00, CI 0.98-1.02, p = 0.845) and > 30% of tumour-infiltrating T cells (HR: 0.38, CI 0.09-1.56, p = 0.175) were not significantly associated with PFS. In this uniformly RT treated population of FeNL, none of the evaluated pre-RT histologic parameters could predict early treatment failure.
局限性猫鼻淋巴瘤（FeNL）的标准治疗方法是放射治疗（RT）。接受RT治疗（无论是否联合化疗）的猫中，有17%-45%会出现早期局部或全身衰竭。本研究的目的是确定治疗前活检特征是否可预测FeNL的早期肿瘤进展。纳入标准包括组织学确诊的FeNL、具有诊断质量的可用石蜡块、RT分期前局限于鼻窦腔、接受调强放疗/影像引导放疗（10×4.2 Gy）且未进行化疗以及至少1年的随访。对所有RT治疗前的活检组织进行复查，并采用CD3、CD20、CD79a、泛细胞角蛋白（pan-CK）和Ki-67免疫组织化学进行评估，同时确定有丝分裂活性指数。主要终点是1年无进展生存期（PFS），并计算风险比（HR）及其置信区间（CI）。28只猫符合纳入标准，均为弥漫性大B细胞淋巴瘤。17只猫（61%）在1年时无进展。在第一年出现进展的11只猫中，2只出现局部进展，2只出现局部和全身进展，7只出现全身进展。有丝分裂指数（HR：1.03，CI 0.9-1.19，p = 0.645）、Ki-67（HR：1.00，CI 0.98-1.02，p = 0.845）以及>30%的肿瘤浸润T细胞（HR：0.38，CI 0.09-1.56，p = 0.175）与PFS均无显著相关性。在这个接受统一RT治疗的FeNL群体中，所评估的RT治疗前组织学参数均无法预测早期治疗失败。
